Trade Hikma Pharmaceuticals PLC - HIK CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.08 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.02529% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003373% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | GBP | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United Kingdom of Great Britain and Northern Ireland | ||||||||
| Commission on trade | 0% |
| Prev. Close | 18.07 |
| Open | 17.64 |
| 1-Year Change | -4.29% |
| Day's Range | 17.64 - 18.75 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2024 | 18.07 | 0.01 | 0.06% | 18.06 | 18.33 | 18.02 |
| Apr 23, 2024 | 18.15 | 0.10 | 0.55% | 18.05 | 18.29 | 18.00 |
| Apr 22, 2024 | 18.05 | 0.08 | 0.45% | 17.97 | 18.27 | 17.97 |
| Apr 19, 2024 | 18.03 | 0.20 | 1.12% | 17.83 | 18.03 | 17.55 |
| Apr 18, 2024 | 17.88 | 0.10 | 0.56% | 17.78 | 17.98 | 17.62 |
| Apr 17, 2024 | 17.60 | 0.03 | 0.17% | 17.57 | 17.88 | 17.53 |
| Apr 16, 2024 | 17.72 | -0.06 | -0.34% | 17.78 | 17.95 | 17.52 |
| Apr 15, 2024 | 18.00 | 0.17 | 0.95% | 17.83 | 18.11 | 17.82 |
| Apr 12, 2024 | 17.99 | -0.24 | -1.32% | 18.23 | 18.32 | 17.76 |
| Apr 11, 2024 | 18.07 | 0.33 | 1.86% | 17.74 | 18.15 | 17.66 |
| Apr 10, 2024 | 17.85 | -0.21 | -1.16% | 18.06 | 18.20 | 17.78 |
| Apr 9, 2024 | 18.07 | -0.13 | -0.71% | 18.20 | 18.30 | 18.07 |
| Apr 8, 2024 | 18.45 | 0.10 | 0.54% | 18.35 | 18.49 | 18.28 |
| Apr 5, 2024 | 18.58 | 0.13 | 0.70% | 18.45 | 18.60 | 18.29 |
| Apr 4, 2024 | 18.68 | 0.32 | 1.74% | 18.36 | 18.77 | 18.36 |
| Apr 3, 2024 | 18.59 | 0.02 | 0.11% | 18.57 | 18.68 | 18.34 |
| Apr 2, 2024 | 18.79 | -0.09 | -0.48% | 18.88 | 18.93 | 18.62 |
| Mar 28, 2024 | 19.22 | 0.40 | 2.13% | 18.82 | 19.34 | 18.80 |
| Mar 27, 2024 | 18.72 | 0.14 | 0.75% | 18.58 | 18.74 | 18.48 |
| Mar 26, 2024 | 18.70 | -0.13 | -0.69% | 18.83 | 18.93 | 18.47 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Hikma Company profile
Discover the latest Hikma share price today with our comprehensive live chart.
Hikma Pharmaceuticals plc. (HIK) creates and sells generic pharmaceutical solutions and products in the USA, North Africa, Europe, and the Middle East; with its headquarters located in London, UK. The company has operations in more than 50 countries and divides its work into three business units: Branded, Injectables, and Generics.
Hikma owns 29 manufacturing plants in 11 countries: Jordan, Saudi Arabia, Algeria, Egypt, Morocco, Tunisia, Sudan, United States, Portugal, Italy and Germany. The Hikma’s branded division offers 499 products in 1,256 dosage strength. The most popular products are: Amoclan, Omnisef, Blopress and Suprax. The injectables division vendors 200 products in 379 dosage forms.
Hikma pharmaceuticals share price is set and traded on the London Stock Exchange (LSE) under the ticker symbol HIK. The company constitutes the FTSE 100 and FTSE 350 Indices.
Hikma made an initial public offering on 11 November 2005, and Hikma pharmaceuticals shares were listed for the first time, raising gross proceeds of $124 million.
Hikma Pharmaceuticals was founded in Amman, Jordan, by Samih Darwazah in 1978. In August 1996, it became the first Arab company to export pharmaceutical products to the US.
The company’s biggest acquisitions include Jazeera Pharmaceutical, Saudi Arabia; Instituto Biochimico Pavese Pharma, Italy; Baxter International, US; Ribosepharm, Germany; Promopharm, Morocco, and Alkan Pharma, Egypt. All of these strategic acquisitions helped Hikma to establish itself as the world’s leading provider in its industry.
In May 2014, Hikma Pharmaceuticals plc significantly increased its presence in the injected medicine market by purchasing assets from the US generic injectable drugs business of Germany's Boehringer Ingelheim for up to $300 million.
The most recent company acquisition was Roxane Laboratories in Columbus, US. It has majorly improved Hikma's position in a non-injectables business in the US market.
Hikma has been recognised as the Company of the Year by the Global Generics and Biosimilars Awards for four years in a row: from 2014 to 2017.
According to Hikma’s latest earnings report, the company delivered strong growth in revenue and profit in 2019 with a group core revenue of $2,203 million (up 6 per cent) and operating profit of $508 million (up 10 per cent).
Follow the Hikma share price today with Capital.com to spot the best trading opportunities. Track all the ups and downs of the HIK stock price and stay on top of the latest price fluctuations with our live Hikma stock chart.
| Industry: | Pharmaceuticals (NEC) |
1 New Burlington Place
LONDON
W1S 2HR
GB
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com